

DESCRIPTION

Source *E. coli*-derived human NM23-H1 protein
Ala2-Glu152
Accession # P15531.1
with a C-terminal 6-His tag

N-terminal Sequence Analysis Ala2

Predicted Molecular Mass 18 kDa

SPECIFICATIONS

SDS-PAGE 18-20 kDa, under reducing conditions.

Activity Measured by its ability to convert thymidine diphosphate and adenosine triphosphate to thymidine triphosphate and adenosine diphosphate in a coupled assay.
The specific activity is >50,000 pmol/min/μg, as measured under the described conditions.

Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl and TCEP. See Certificate of Analysis for details.

Activity Assay Protocol

Materials

- Assay Buffer: 50 mM Tris, 10 mM MgCl₂, 100 mM KCl, pH 7.5
- Recombinant Human NM23-H1 His-tag (rhNM23-H1) (Catalog # 10495-NM)
- Substrate: Thymidine 5'-Diphosphate (TDP) (Sigma, Catalog # T9375), 40 mM stock in 10 mM Sodium Borate, pH 9.0
- Recombinant Human PKM2 (rhPKM2) (Catalog # 7244-PK)
- Recombinant Human Lactate Dehydrogenase A/LDHA (rhLDHA) (Catalog # 9158-HA)
- Adenosine 5'-triphosphate (ATP) (Sigma, Catalog # A7699), 400 mM stock in deionized water
- β-Nicotinamide adenine dinucleotide, reduced disodium salt hydrate (β-NADH) (Sigma, Catalog # N8129), 20 mM stock in 0.1 M Sodium Borate, pH 9.0
- Phospho(enol)pyruvic acid (PEP) (Sigma, Catalog # P0564), 50 mM stock in deionized water
- 96-well clear Plate (Catalog # DY990)
- Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

Assay

- Prepare Reaction Mixture containing 20 μg/mL rhPKM2, 5 μg/mL rhLDHA, 4 mM ATP, 400 μM β-NADH, 2 mM PEP and 2 mM TDP in Assay Buffer.
- Incubate Reaction Mixture at room temperature for 5 minutes.
- Dilute rhNM23-H1 to 0.01 ng/μL in Assay Buffer.
- In a plate, load 50 μL of 0.01 ng/μL rhNM23-H1 and start the reaction by adding 50 μL of Reaction Mixture. Include a Control containing 50 μL of Assay Buffer and 50 μL of Reaction Mixture.
- Read at an absorbance of 340 nm in kinetic mode for 5 minutes.
- Calculate specific activity:

$$\text{Specific Activity (pmol/min/μg)} = \frac{\text{Adjusted } V_{\text{max}}^* (\text{OD/min}) \times \text{well volume (L)} \times 10^{12} \text{ pmol/mol} \times (-1)}{\text{ext. coeff}^{**} (\text{M}^{-1}\text{cm}^{-1}) \times \text{path corr.}^{***} (\text{cm}) \times \text{amount of enzyme (μg)}}$$

*Adjusted for Control

**Using the extinction coefficient 6220 M⁻¹cm⁻¹

***Using the path correction 0.32 cm

Note: the output of many spectrophotometers is in mOD

Final Assay Conditions

Per Well:

- rhNM23-H1: 0.0005 μg
- TDP: 1 mM
- ATP: 2 mM
- β-NADH: 200 μM
- PEP: 1 mM
- rhPKM2: 1 μg
- rhLDHA: 0.25 μg

PREPARATION AND STORAGE


Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 6 months from date of receipt, -20 to -70 °C as supplied.
- 3 months, -20 to -70 °C under sterile conditions after opening.


DATA

Enzyme Activity



Recombinant Human NM23-H1 His-tag Protein Enzyme Activity
Recombinant Human NM23-H1 His-tag (Catalog # 10495-NM) is measured by its ability to convert thymidine diphosphate and adenosine triphosphate to thymidine triphosphate and adenosine diphosphate in a coupled assay.

SDS-PAGE



Recombinant Human NM23-H1 His-tag Protein SDS-PAGE. 2 µg/lane of Recombinant Human NM23-H1 His-tag Protein (Catalog # 10495-NM) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-20 kDa.

BACKGROUND

Non-metastatic Protein 23 Homolog 1 (NM23-H1), also known as Nucleoside diphosphate kinase A (NDPK-A), is a group 1 member of the NDPK family encoded by the NME1 (non metastatic cell) gene (1). NDPKs are well-known as housekeeping genes that maintain the balance of nucleoside triphosphate levels by transferring a phosphate group from a nucleoside triphosphate to nucleoside diphosphate. NM23-H1 is a cytosolic protein that forms active hexamers composed of a trimer of dimers (2,3). The active hexamer contains a "head" region with substrate binding and catalytic activity as well as a Kpn loop and C-terminal extensions that stabilize the structure (2,3). NM23-H1 (NDPK-A) shares significant homology with NM23-H2 (NDPK-B), with 88% identity (3). In spite of significant homology and catalytic function between these isoforms, the differing amino acids on the lateral surface of the hexamers lead to specific interactions with other proteins and ultimately result in diverging cellular distribution and function in cells (1). NM23-H1 was the first reported metastasis suppressor gene (4) and plays a role in cell adhesion, migration and motility, and signaling and proteolysis (5-7). Suppression activity has been demonstrated in many cancers although the mechanism involved is uncertain (1,7). NM23-H2 has been reported to have several functions: enzymatic function as a protein histidine kinase with ATP-citrate lyase and annexin A1 as direct targets (5), exonuclease activity (8), NDPK activity (1), and also forms a complex with the cystic fibrosis transmembrane conductance regulator (CFTR) (9) in regulation of chloride channels, other signaling pathways, and gene regulation (1,10,11).

References:

1. Boissan, M. *et al.* (2018) *Lab. Invest.* **98**:164.
2. Janin, J. *et al.* (2000) *J. Bioenerg. Biomembr.* **32**:215.
3. Webb, P.A. *et al.* (1995) *J. Mol. Biol.* **251**:574.
4. Steeg, P.S. *et al.* (1988) *J. Natl. Cancer Inst.* **80**:200.
5. Attwood, P.V. *et al.* (2018) *Lab. Invest.* **98**:283.
6. Khan, I. *et al.* (2019) *Cancer Res.* **79**:4689.
7. Matyasi, B. *et al.* (2020) *Pathol. Oncol. Res.* **26**:49.
8. Fan, Z. *et al.* (2003) *Cell* **112**:659.
9. Borthwick, L.A. *et al.* (2016) *PloS One.* **11**:e0149097.
10. Ma, W. *et al.* (2008) *Biochem. Biophys. Res. Commun.* **371**:425.
11. Zheng, S. *et al.* (2019) *FEBS Lett.* **593**:80.